Pegcetacoplan not checked

Apellis Pharmaceuticals, Inc. · APL-2

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
21 in total · 8 in the EU
Targets
 

What this is

How it works
Blocks part of the complement system, a branch of the immune system that can attack the body's own cells.Complement Inhibitor FDA class
How it’s given
“Solution for infusion for subcutaneous use according to drug use in the real world.”In the company’s words, NCT07746895 on ClinicalTrials.gov
Tested for
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 trials), C3 Glomerulopathy (C3G), C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) and 10 more
Main trialPhase 4
“The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.”In the company’s words, NCT07746895 on ClinicalTrials.gov
Other names
APL-2
Given with
Soliris (Alexion Pharm)Other companies’ drugs in its trials

Other drugs for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

All 3 drugs for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Coming up5

Changes1

Last 90 days

Trials21

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 31 Dec 2031 Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
Phase 3Active, not recruiting Jul 2027 An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Phase 3Recruiting 17 Jan 2031 A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
Phase 2/3Recruiting Oct 2029 A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Phase 2Recruiting Dec 2028 A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3Completed 14 Nov 2019 Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3Completed 21 Jun 2021 Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Phase 3Completed 23 Jun 2021 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
Phase 3Completed 28 Jun 2021 A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Phase 3Completed 26 Jun 2024 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Phase 3Completed 4 Sep 2025 Pegcetacoplan Long Term Safety and Efficacy Extension Study
Phase 3Completed 5 Sep 2025 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Phase 3Completed 12 Dec 2025 Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Phase 3Withdrawn Jun 2029 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Phase 2Completed 16 Apr 2020 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Phase 2Completed 12 Sep 2022 Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Phase 2Completed 27 Feb 2023 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Phase 2Terminated 31 Mar 2023 MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
Phase 1Completed 22 Oct 2018 A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Phase 1Completed 26 Aug 2019 Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
Phase 1Completed 1 Apr 2021 Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pegcetacoplan

Following is part of Solo: you see every change to Pegcetacoplan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in